Inactive Instrument
ANTA PHAR Stock Nasdaq
Stocks
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 18-07-02 | Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index | CI |
| 18-06-27 | Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index | CI |
| Market Cap | 681K 597K 564K 514K 962K 65.24M 969K 6.75M 2.61M 33.33M 2.56M 2.5M 107M | P/E 2016 |
-0.4x | P/E 2017 | -0.58x |
|---|---|---|---|---|---|
| Enterprise Value | -1.52M -1.33M -1.26M -1.14M -2.14M -145M -2.16M -15.03M -5.82M -74.2M -5.69M -5.57M -238M | EV / Sales 2016 |
44,069,434x | EV / Sales 2017 | - |
| Free-Float |
100% | Yield 2016 * |
-
| Yield 2017 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.30% | +1.50% | +57.79% | +85.24% | 72.26B | |
| -0.05% | -2.70% | +38.19% | +86.90% | 60.24B | |
| +0.75% | +0.75% | +34.85% | +21.09% | 27.73B | |
| -0.64% | -3.62% | -17.67% | +352.74% | 25.73B | |
| -1.08% | -1.06% | -1.16% | -4.97% | 24.75B | |
| +0.57% | +1.06% | +24.67% | -8.31% | 20.74B | |
| -1.70% | -2.12% | +150.24% | +323.16% | 15.06B | |
| -0.73% | +1.24% | +42.79% | +158.73% | 14.41B | |
| -2.53% | -8.15% | -8.15% | +483.59% | 14.23B | |
| Average | -0.97% | +0.44% | +35.73% | +166.46% | 30.57B | |
| Weighted average by Cap. | -1.19% | +0.31% | +37.20% | +126.46% |
| 2016 | 2017 | |
|---|---|---|
| Net sales | 0.14 0.13 0.12 0.11 0.21 13.9 0.21 1.44 0.56 7.1 0.54 0.53 22.82 | - |
| Net income | -55.52M -48.72M -46.02M -41.93M -78.5M -5.32B -79.06M -551M -213M -2.72B -208M -204M -8.74B | -26.87M -23.58M -22.27M -20.3M -37.99M -2.58B -38.27M -267M -103M -1.32B -101M -98.72M -4.23B |
| Net Debt | -20.84M -18.29M -17.27M -15.74M -29.47M -2B -29.68M -207M -80.06M -1.02B -78.26M -76.56M -3.28B | -2.2M -1.93M -1.82M -1.66M -3.1M -210M -3.13M -21.78M -8.44M -108M -8.25M -8.07M -346M |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
